1. Meaning 

Clinical Research Ethics Governance is the system of legal rules, ethical principles, institutional procedures, regulatory supervision and accountability mechanisms that ensure clinical research is scientifically valid, socially beneficial and respectful of the rights, safety, dignity and autonomy of research participants.

It applies to clinical trials of medicines, vaccines, medical devices, gene therapies and other biomedical interventions, as well as relevant observational studies, genetic research and research using human biological samples or health data.

The central question is: How can scientific progress be achieved without exploiting or unjustifiably endangering human participants?

In India, the principal framework includes the Indian Council of Medical Research (ICMR) ethical guidelines, the New Drugs and Clinical Trials Rules, 2019, applicable provisions of the Drugs and Cosmetics Act, 1940, and constitutional protections and judicial decisions.

The ICMR's National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017 provide a foundational ethical framework. ICMR also lists more recent supplementary guidance, including its 2026 operational guidelines for single ethics review of multicentre research.

Bioethics Unit+2

2. Objectives of clinical research ethics governance

The main objectives are:

Protection of participants: Prevent avoidable physical, psychological, social and economic harm.

Informed consent: Ensure voluntary participation based on adequate understanding.

Scientific validity: Prevent exposing people to risks through poorly designed or unnecessary research.

Independent ethical review: Require impartial scrutiny of proposed research before it begins.

Fair participant selection: Prevent discrimination, coercion and exploitation of vulnerable groups.

Transparency and accountability: Maintain reliable records of approvals, adverse events, trial results and financial interests.

Compensation and remedies: Establish appropriate protections when research-related injury occurs.

Public trust: Ensure that scientific innovation serves participants and society rather than commercial interests alone.

These objectives reflect four foundational ethical principles: respect for persons, beneficence, non-maleficence and justice.

OECD AI+1

3. Fundamental principles

A. Respect for autonomy

Participants must be able to decide freely whether to participate, continue participating or withdraw, subject to legitimate procedural requirements and without improper penalties.

A researcher must not treat a patient's desperation for treatment as permission to enrol that person in an experimental intervention without meaningful consent.

B. Beneficence

Researchers and sponsors should design studies to produce valuable scientific or medical knowledge and, where applicable, potential health benefits. Risks must be justified by the anticipated benefits and social value.

C. Non-maleficence

The principle of primum non nocere—first, do no harm—requires the reduction, prevention and active monitoring of foreseeable risks. It does not mean that every research risk is prohibited; rather, unacceptable or unjustified risks must not be imposed.

D. Justice

The burdens and benefits of research must be distributed fairly. Researchers should not recruit disadvantaged communities merely because they are easier to influence, nor exclude groups without a scientifically or ethically justified reason.

E. Scientific integrity

Fabricated data, manipulated results, undisclosed conflicts of interest and selective reporting can expose participants to risk while undermining the value of research. Ethical governance therefore requires scientific quality as well as procedural compliance.

4. Legal and regulatory framework in India

A. Constitution of India

Article 21: Protection of life and personal liberty; provides a constitutional foundation for bodily autonomy, dignity and protection against arbitrary interference.

Article 14: Equality before the law and protection against arbitrary state action.

Article 32: Access to the Supreme Court for enforcement of fundamental rights.

Article 226: High Courts' power to issue writs for enforcement of rights and other lawful purposes.

These provisions are especially relevant when government authorities approve, supervise or fail to adequately regulate research involving human participants.

B. Drugs and Cosmetics Act, 1940, and New Drugs and Clinical Trials Rules, 2019

These establish the statutory framework for regulated new-drug clinical trials, regulatory permissions, ethics committee requirements, safety reporting and participant protections. The precise requirements depend on the type of product and study.

The Central Drugs Standard Control Organisation (CDSCO) and the Drugs Controller General of India (DCGI) perform central regulatory functions under the applicable framework.

ClinRegs+1

C. ICMR National Ethical Guidelines, 2017

These guidelines address ethical review, consent, vulnerability, privacy, biological materials, research involving children, conflicts of interest and responsible research conduct. They are an essential reference for Indian biomedical and health research, although they are not, by themselves, a statute. Applicable legislation and binding regulatory requirements take precedence where relevant.

Indian Council of Medical Research+1

D. International ethical standards

The Nuremberg Code, Declaration of Helsinki and CIOMS International Ethical Guidelines provide influential standards for voluntary consent, independent review, proportional risk, protection of vulnerable participants and responsible publication. Their legal force depends on the applicable jurisdiction and their incorporation into domestic rules, policies or professional obligations.

Ethics committees: the institutional safeguard

An Institutional Ethics Committee (IEC), also called an Ethics Committee (EC), independently reviews the ethical acceptability of research. For regulated clinical trials in India, the applicable registration and approval requirements under the New Drugs and Clinical Trials Rules must be followed. Ethics approval and regulatory permission are distinct requirements; one does not automatically replace the other.

ClinRegs+1

An ethics committee ordinarily examines:

Scientific validity and social value of the protocol.

Whether foreseeable risks are justified by potential benefits.

The participant information sheet and consent procedure.

Recruitment methods, payments and reimbursement.

Safeguards for children and other vulnerable participants.

Confidentiality, data security and biological-sample use.

Safety monitoring, adverse-event reporting and compensation arrangements.

Conflicts of interest and the independence of investigators.

Approval is not the end of ethical supervision. Amendments, emerging safety information, serious adverse events and changes to consent procedures may require additional review or regulatory action.

5. Informed consent and participant autonomy

Informed consent is one of the most important requirements of clinical research ethics governance. A signature on a consent form does not automatically establish ethically valid consent.

A sound consent process generally requires the following elements:

Disclosure: Explain the purpose, procedures, duration, foreseeable risks, potential benefits and available alternatives.

Understanding: Present information in a language and format the participant can reasonably understand.

Voluntariness: Avoid threats, undue influence and coercive recruitment.

Decision-making capacity: Assess whether the person can make the relevant decision; apply appropriate safeguards when capacity is impaired.

Documentation: Record consent using the legally and ethically applicable method.

Continuing consent: Communicate significant new information that could affect willingness to continue.

Participants should ordinarily be told that the intervention may be experimental, that personal benefit is not guaranteed, and that withdrawal is permitted without improper retaliation.

Special situations

Children: Require the applicable parental or legally authorised permission and age-appropriate assent safeguards, subject to the governing rules and circumstances.

Emergency research: Any exception to ordinary consent requirements must satisfy the specific legal and ethical conditions; urgency alone does not create a blanket exemption.

Genetic research: Additional care is needed for genetic privacy, familial implications, future sample use and the possibility of unexpected findings.

Audio-video recording: Where required by applicable law or regulatory directions, recording must be conducted with appropriate consent, confidentiality and secure handling of the record.

In the Indian clinical-trial litigation discussed below, the Supreme Court addressed safeguards for documenting the informed-consent process, including audio-video recording in specified circumstances.

SpotLaw App+1

6. Landmark case laws on clinical research ethics governance

The following cases are particularly relevant to Indian clinical-trial regulation, informed consent and participant protection. Some are direct clinical-trial cases; others establish broader principles of autonomy and medical consent that are useful by analogy.

Case 1: Swasthya Adhikar Manch, Indore v. Union of India (2013–2014 proceedings)

Supreme Court of India · W.P. (C) No. 33 of 2012 and connected petitions

Facts: The proceedings raised concerns about the approval and conduct of clinical trials in India, including deaths and serious adverse events among trial participants, regulatory oversight and compensation.

Issues:

Whether the clinical-trial approval process adequately protected participants.

Whether risk-benefit assessment and the need for new treatments were properly evaluated.

Whether informed consent and compensation safeguards were sufficient.

Court's approach: In its orders of 30 September 2013 and 21 October 2013, the Supreme Court scrutinised the approval and supervision framework. Its subsequent orders addressed informed-consent safeguards, adverse events and compensation. On 21 April 2014, the Court directed that applications for new chemical entities and global clinical trials include specific consideration of risk-benefit assessment, innovation compared with existing therapies and unmet medical need.

CaseMine+2

Legal significance: The proceedings demonstrate that clinical-trial governance must involve more than administrative approval. It must assess scientific necessity, participant safety, consent, monitoring and accountability.

Principle: Regulatory approval should be supported by a reasoned evaluation of both the proposed research's value and the risks imposed on participants.

Case 2: Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India · (2008) 2 SCC 1

Facts: A patient consented to a diagnostic procedure under anaesthesia. A more extensive surgical procedure was performed without obtaining her prior consent for that additional procedure.

Issue: What constitutes valid consent for medical intervention?

Decision: The Supreme Court explained that valid consent must be voluntary and based on adequate information about the nature and purpose of the procedure, its benefits and risks, and available alternatives. Consent to one procedure does not ordinarily authorise a materially different procedure.

Relevance to clinical research: Although this was a medical-treatment case rather than a clinical-trial case, its reasoning is relevant when researchers propose materially different procedures, additional sample collection or interventions outside the scope of the original consent.

Principle: Consent is procedure-specific and cannot be treated as unrestricted permission for any intervention a professional considers desirable.

Case 3: Common Cause v. Union of India (2018)

Supreme Court of India · (2018) 5 SCC 1

Facts: The case concerned dignity, bodily autonomy and the right to refuse medical treatment, including end-of-life decisions.

Decision: The Supreme Court recognised the constitutional importance of autonomy and dignity in decisions concerning medical treatment and end-of-life care.

Relevance to clinical research: The case supports the broader constitutional understanding that medical decision-making must respect the individual's autonomy. Research participation must not be forced merely because investigators, institutions or sponsors believe the research is beneficial.

Principle: The value of a medical or scientific objective does not automatically override an individual's legally protected autonomy.

Note: This case concerns end-of-life decision-making, not the approval of clinical trials directly.

Case 4: Schloendorff v. Society of New York Hospital (1914)

Supreme Court of New York, Appellate Division · 105 N.E. 92 (N.Y. 1914)

Facts: A patient agreed to an examination under anaesthesia but had not authorised an operation. A tumour was removed during the procedure.

Decision: The judgment became a landmark expression of the principle that an adult of sound mind has authority to determine what is done to their body.

Relevance: The case helped shape modern consent doctrine. In research settings, it illustrates why a participant's body cannot be treated merely as an instrument for producing scientific knowledge.

Principle: Physical intervention without legally adequate authorisation may violate bodily autonomy.

Case 5: Salgo v. Leland Stanford Jr. University Board of Trustees (1957)

California Court of Appeal · 317 P.2d 170 (Cal. Ct. App. 1957)

Facts: A patient suffered paralysis following an aortography procedure and alleged that material risks had not been adequately disclosed.

Decision: The court developed an influential formulation of the duty to disclose material information necessary for intelligent consent.

Relevance: Researchers should not conceal significant risks, uncertainties, experimental features or reasonable alternatives from prospective participants.

Principle: Consent must be informed, not merely formally documented. This US medical-negligence decision is persuasive background, not binding Indian law.

NCBI Bookshelf

Case 6: Canterbury v. Spence (1972)

US Court of Appeals for the District of Columbia Circuit · 464 F.2d 772

Facts: The case involved allegations that a surgeon had failed to disclose a material risk associated with surgery.

Decision: The court articulated a patient-oriented approach to disclosure, focusing on information material to a reasonable patient's decision.

Relevance: In clinical research, information about foreseeable serious adverse effects, uncertainty of benefit and alternatives to participation may materially affect the decision to enrol.

Principle: Disclosure should be assessed from the perspective of the person's decision, not solely by what the professional considers customary.

Important distinction: This is a US treatment-consent case, not an Indian clinical-research judgment. Its relevance is comparative and conceptual.

7. Additional legal authorities and ethical foundations

These instruments have different legal statuses. Ethical declarations and guidance documents should not automatically be described as statutes or binding judicial precedents. Their enforceability depends on the applicable legislation, regulatory framework, institutional requirements and professional obligations.

Indian Council of Medical Research+2

8. Clinical research injury, compensation and liability

A functioning governance system must provide meaningful remedies when a participant suffers harm.

Under India's clinical-trial framework, sponsors and other responsible parties may have obligations concerning medical management, reporting and compensation for trial-related injury or death, as applicable under the governing rules.

In the Swasthya Adhikar Manch proceedings, the Supreme Court examined the number of trial participants who had experienced serious adverse events and the status of compensation. The proceedings helped bring participant protection and regulatory accountability into sharper focus.

Indian Kanoon+1

Who may be held accountable?

1. Sponsor

May face regulatory or civil consequences for failures involving trial design, safety monitoring, reporting, product quality, insurance or compensation, depending on the applicable obligations and evidence.

2. Principal investigator and research team

May be accountable for negligent conduct, deficient consent, protocol violations, inaccurate records or failure to report safety concerns.

3. Ethics committee

May face institutional, professional or regulatory consequences where it fails to discharge its assigned responsibilities. Liability is not automatic merely because an adverse event occurs.

4. Regulatory authorities

May be subject to judicial scrutiny where public-law duties are breached, approvals are arbitrary or applicable safeguards are not enforced.

5. Research institution

May face consequences for inadequate supervision, deficient institutional procedures, recordkeeping failures or other breaches attributable to its conduct.

Distinguishing adverse events from legal liability

An adverse event occurring during a trial does not necessarily establish that the trial caused it or that someone was negligent. Conversely, a participant's entitlement to a regulatory compensation mechanism may not depend on proving every element of ordinary negligence.

A proper assessment distinguishes:

Temporal association from scientifically assessed causation.

Foreseeable and properly disclosed risks from undisclosed or unjustified risks.

Unavoidable complications from preventable harm.

Regulatory compensation obligations from civil damages and other remedies.

The applicable rules, the nature of the injury, the evidence and the relevant legal cause of action determine the outcome.

9. Governance across the clinical research lifecycle

Clinical research ethics is a continuous process rather than a one-time approval exercise.

Stage 1 — Research design

Assess scientific merit, social value, participant selection, feasibility and risk-benefit balance.

Stage 2 — Independent review and permissions

Obtain required ethics committee approvals, regulatory permissions and prospective trial registration where applicable.

Stage 3 — Recruitment and consent

Ensure voluntary participation, accurate disclosure, appropriate documentation and safeguards for vulnerable participants.

Stage 4 — Trial conduct and monitoring

Monitor safety, document deviations, report adverse events, review emerging evidence and update participants when required.

Stage 5 — Reporting and accountability

Analyse and report results accurately, protect confidential data, disclose relevant findings and address injuries or complaints.

10. Ethical governance of emerging clinical technologies

Modern clinical research creates additional governance challenges, especially in biotechnology and data-intensive medicine.

India's ICMR guidance includes specific materials on AI in biomedical research, research involving children and other specialised research areas. Such supplementary guidance should be read alongside the applicable legislation and trial-specific requirements.

Bioethics Unit+1

11. Practical example

Suppose a pharmaceutical sponsor proposes a trial of a new cancer drug in an Indian hospital.

The drug has potential benefits, but its long-term risks remain uncertain.

An ethically sound governance process would require the responsible parties to:

Establish a scientifically credible rationale for the trial.

Obtain all required ethics and regulatory approvals.

Explain the experimental nature of the drug, foreseeable risks, alternatives and uncertainty of benefit.

Obtain valid consent without exploiting patients' desperation for treatment.

Apply appropriate eligibility criteria and additional protections for vulnerable participants.

Monitor adverse events and report them within applicable timelines.

Review new safety information and modify, suspend or terminate the trial where required.

Provide medical management and compensation where the governing rules require it.

Protect patient records and biological samples.

Report findings honestly, including unfavourable or inconclusive results.

If the sponsor conceals a serious known risk, the investigator obtains consent through misleading assurances, or the institution ignores a material safety signal, the conduct may violate ethical standards and applicable legal duties. The precise legal consequences depend on the facts, the applicable rules and the evidence.

12. Critical analysis: strengths and challenges

Strengths

Independent ethical review creates a safeguard against sponsor or investigator self-interest.

Informed consent recognises participant autonomy.

Adverse-event monitoring and compensation mechanisms support accountability.

Judicial oversight can expose gaps in regulatory practice.

Trial registration and responsible reporting promote transparency.

Continuing challenges

Ethics committees may face resource constraints or conflicts of interest.

Consent forms may be technically complete but difficult for participants to understand.

Participants may misunderstand experimental treatment as guaranteed therapy.

Safety reporting and compensation disputes can be complex.

Cross-border trials create questions about data access, responsibility and equitable benefits.

Digital and genetic research can create privacy risks extending beyond the trial itself.

The central challenge is to make ethical safeguards effective in practice, rather than treating them as paperwork completed to obtain approval.

13. Conclusion

Clinical Research Ethics Governance is a framework of participant protection, independent oversight, scientific integrity, informed consent and legal accountability. It seeks to ensure that medical progress is achieved through research that is scientifically justified and ethically acceptable.

In India, the Swasthya Adhikar Manch proceedings are particularly important for understanding judicial scrutiny of clinical-trial approvals, risk-benefit assessment, consent safeguards and compensation. Samira Kohli provides a significant domestic precedent on the scope of valid consent, while Common Cause reinforces the broader constitutional importance of dignity and autonomy. Comparative decisions such as Schloendorff, Salgo and Canterbury help explain the historical development of consent doctrine.

Taken together, these authorities support a key proposition: scientific advancement cannot, by itself, justify inadequate consent, unjustified risk or the neglect of research participants' rights.

For further study, the primary Indian materials are the ICMR National Ethical Guidelines, the ICMR ethical-guidelines portal and the Supreme Court proceedings in Swasthya Adhikar Manch v. Union of India.

Academic note: This is a general legal and ethical overview, not advice on a specific trial, injury claim or regulatory application. For legal submissions, verify the exact wording and current status of the applicable rules and the particular judicial order being relied upon.